Latest Schedule 13G passive stakes

Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.6% of EPAM Systems Inc. common stock, totaling 2,410,977 shares.

Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.6% of EPAM Systems Inc. common stock, totaling 2,410,977 shares.

Laurence W. Lytton has updated his beneficial ownership filing for Aprea Therapeutics, Inc., reporting a 3.2% stake.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have updated their beneficial ownership filing for Newbury Street II Acquisition Corp.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have updated their beneficial ownership filing for Newbury Street II Acquisition Corp.

Invesco Ltd. has updated its beneficial ownership filing for Element Solutions Inc, now holding 5.2% of the company's common stock.

Invesco Ltd. has updated its beneficial ownership filing for Element Solutions Inc, now holding 5.2% of the company's common stock.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting a de minimis beneficial ownership of H&E Equipment Services, Inc. common stock.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting a de minimis beneficial ownership of H&E Equipment Services, Inc. common stock.

Laurence W. Lytton and the Lytton-Kambara Foundation have jointly filed a Schedule 13G, reporting a combined 9.99% beneficial ownership in IN8BIO, Inc.

Invesco Ltd. has disclosed beneficial ownership of 5.0% of Chord Energy Corp's common stock, reporting 2,817,980 shares.

Invesco Ltd. has disclosed beneficial ownership of 5.0% of Chord Energy Corp's common stock, reporting 2,817,980 shares.

Brandes Investment Partners, L.P. has reported an increased beneficial ownership of Graham Corp's common shares, now holding 9.2% of the class.

Laurence W. Lytton and the Lytton-Kambara Foundation collectively hold a 9.9% stake in Capstone Energy Plus, Inc., as disclosed in an amended Schedule 13G filing.

Invesco Ltd. has disclosed beneficial ownership of 6.2% of Charles River Laboratories International Inc.'s common stock as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 6.2% of Charles River Laboratories International Inc.'s common stock as of June 30, 2026.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Class A Ordinary Shares of Fortress Value Acquisition Corp. V.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Class A Ordinary Shares of Fortress Value Acquisition Corp. V.

Laurence W. Lytton has reported beneficial ownership of 100,521 shares, representing 6.8% of DNA X, Inc.'s common stock, as of June 30, 2026.

Invesco Ltd. has reported beneficial ownership of 5.4% of Canaan Inc.'s American Depository Receipts, totaling over 606 million shares.

Invesco Ltd. has reported beneficial ownership of 5.4% of Canaan Inc.'s American Depository Receipts, totaling over 606 million shares.

Invesco Ltd. has disclosed beneficial ownership of 5.5% of Atmus Filtration Technologies Inc.'s common stock as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 5.5% of Atmus Filtration Technologies Inc.'s common stock as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 1,650,643 shares, representing 7.4% of ArcBest Corp's common stock, as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 1,650,643 shares, representing 7.4% of ArcBest Corp's common stock, as of June 30, 2026.

Laurence W. Lytton has reported beneficial ownership of 5,592,972 shares, representing 5.2% of Codexis, Inc. common stock, as of June 30, 2026.

Laurence W. Lytton and the Lytton-Kambara Foundation have jointly filed a Schedule 13G, reporting a combined beneficial ownership of approximately 9.9% in Scientific Industries Inc., indicating a substantial passive investment.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Esperion Therapeutics, Inc. common stock as of June 30, 2026.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Esperion Therapeutics, Inc. common stock as of June 30, 2026.

Laurence W. Lytton has reported a beneficial ownership of 9.6% in MDxHealth SA's ordinary shares.